Form 4: Pacira BioSciences COO Sells Shares Under 10b5-1 Trading Plan

Pacira BioSciences' Chief Operating Officer, Daryl Gaugler, sold 500 shares of common stock at $19.76 per share on December 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Daryl Gaugler, the Chief Operating Officer of Pacira BioSciences, sold 500 shares of the company's common stock on December 13, 2024.
• The sale was executed at a price of $19.76 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan.
• Following the transaction, Mr. Gaugler directly owns 115,199.952 shares of Pacira BioSciences common stock.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive under a pre-arranged plan, which is neither particularly positive nor negative.

Risks

• Sales by company executives can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and sales under 10b5-1 plans are generally viewed as routine and pre-planned.

Comparison to Industry Standards

• Sales by executives are common across the pharmaceutical and biotech industries.
• Rule 10b5-1 plans are a standard practice to avoid accusations of insider trading.
• The volume of shares sold is relatively small compared to the total outstanding shares of Pacira BioSciences.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial position.

Key Dates

Keywords

Pacira BioSciences, PCRX, Daryl Gaugler, insider trading, stock sale, Rule 10b5-1, executive transaction, common stock